



## T Cell and Tumor Immunotherapy

Guest Editors:

**Dr. Raghendra Srivastava**

Center for Immunotherapy and  
Precision Immuno-Oncology  
(CITI), Lerner Research Institute,  
Cleveland Clinic, 2111 E. 96th St.  
NB4-37, Cleveland, OH 44106,  
USA

**Dr. Anil Shanker**

Office for Research and  
Innovation, Meharry Medical  
College, Nashville, TN 37208, USA

Deadline for manuscript  
submissions:

**31 July 2024**

### Message from the Guest Editors

Dear Colleagues,

There are billions of T cells in the body and they play a vital role in immunity. However, only a small percentage of T cells exert anti-tumor immune responses. The tumor microenvironment (TME) is an environment that is often infiltrated by T cells which attack tumor cells. However, these a small percentages of T cells encounter massive tumor-mediated immune suppression when they are infiltrated into the TME.

Overall, through genomic-based biomarkers, transcriptome analysis of TMEs, T cell receptor (TCR) diversity, and microbial diversity in TMEs, we are able to have a much better understanding of TMEs.

We believe that by furthering our knowledge on the TME, we can gain a better understanding of how cancer cells and immune cells interact with their environment, and how the immune system can be more effectively activated to fight cancer.

We would like to invite researchers to submit original research articles and reviews that will improve our understanding of TMEs. We recommend researchers submit work related to the TME, the diversity of TCRs, the diversity of microbes, and genomics-based correlation studies related to the TME.





# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI